Our group has continued to work on our main overarching project the Migraine Adaptive Brain Program (MAB). During 2022, our research has focused on 3 main areas: preclinical, translational and clinical. – Animal Brain & Cell Adaptive Lab: we have started research projects focused on studying inflammation in the trigeminovascular system, using behavior, molecular, neurophysiology techniques- Gene-Environment Lab: we have continued to work on our epigenetic, transcriptomic and molecular research, which is focused on diagnosis and target-driven therapeutics- Sense, Rhythm & Connectivity lab: we have focused on analyzing and publishing experiments which were done in the last 3 years of research.- Clinical MAB program: we have worked on 3 large investigator-driven projects which have finished their patient inclusion.We have participated in 19 industry-driven clinical trials, including 240 patients, 559 visits and testing 8 different active drugs on adults and children.

Group Leader
Patricia Pozo Rosich

Principal Investigator (PI)
Marta Torres-Ferrus

Researchers
Marta Vila-Pueyo, Edoardo Caronna, Nara Ikumi, Erika Araya

PhD Students
Alicia Alpuente, Victor J Gallardo, Angela Marti, Jordi Rovira

Lab Technicians
Laila Asskour

Nursing and Technical Staff
Eulalia Gine, Raquel Lastra, Anna de la Torre

28

PUBLICATIONS

82.1%

%Q1

240

IMPACT FACTOR

8.57

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P
Salivary CGRP and erenumab treatment response: towards precision medicine in migraine
Ann Neurol 2022;92:846-859
DOI: doi: 10.1002/ana.26472
IF: 10.42

Gallardo VJ, Alpuente A, Pozo-Rosich P
Association of a cyclical migraine phenotype with disease progression: a one-year time series analysis
Neurology 2022;99(12):e1326-e1334.
DOI: doi: 10.1212/WNL.0000000000200887
IF: 11.36

Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B.
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial
Lancet Neurol 2022;21(7):597-607
DOI: doi: 10.1186/s10194-021-01366-9
IF: 59.935

Gallardo VJ, Shapiro RE, Caronna E, Pozo-Rosich P
The relationship of headache as a symptom to COVID-19 survival: a systematic review and meta-analysis of survival of 43,169 inpatients with COVID-19
Headache 2022;62(8):1019-1028.
DOI: doi: 10.1111/head.14376
IF: 5.311

Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, Membrilla JA, Caronna E, Gonazalez-Martinez A, Mencia AS, Segura T, Gonzalez-Garcia N, Diaz de Teran J, Gallardo VJ, Gago-Veiga AB, Ballve A, Trigo-Lopez J, Sastre-Real A, Llaurado A, Cornejo A, de Lorenzo I, Guerrero-Peral A, Pozo-Rosich P
Post-COVID-19 persistent headache: a multicentric 9-months follow-up study of 905 patients
Cephalalgia 2022
DOI: doi: 10.1177/03331024211068074
IF: 6.075

AhEAD: Algoritmo de predicción de Eficacia de respuesta A tratamiento preventivo en pacientes con migraña crónica: marcaDores biológicos y clínicos
Principal Investigator: Patricia Pozo-Rosich
Agency: Proyectos de investigación de Medicina Personalizada de Precisión - Instituto Salud Carlos III
Funding: 72,000€
Period: 2019-2023

BIOMIGA: a multidisciplinary approach to biomarkers in migraine                                                                                                        
Principal Investigator: Patricia Pozo-Rosich
Agency: ERANet Neuron - Instituto Investigación Carlos III
Funding: 100.000€
Period: 2019-2023

eCOREs